


# Best Antibody Development & Production Biotech Company 2022

**A European company involved in the development, manufacture, and marketing of polyclonal antibodies for cell biology research, SICGEN was founded in 2009. It hit the ground running with the development, production, and supply of new antibodies for an international market, and since then, it has made a name for itself with its continuously innovative and specific work. With its holistic and comprehensive production – specifically in antibodies that are in notoriously short supply – it has become a critical cornerstone in the medical technology market, one that has allowed it a competitive advantage.**

SICGEN, a company founded to manufacture and market polyclonal antibodies for cell biology research, has earned a huge number of awards over its time in operation, allowing it to grow from strength to strength. Led by Dr José Ramalho – a Portuguese scientist – and two other co-founders, SICGEN began life in 2009, and was established with the goal of creating a highly dedicated and specific research institute. With the backing of the NEOTEC Portuguese Initiative, catalysed by Dr Ramalho's 2009 move to NOVA University in Lisbon, the founder has continued research into cell biology and the development of new antibodies; to this day, he owns 50% of the company's shares.

Operating out of a lab and livestock facility in Coimbra, it boasts a huge and exemplary production unit. Indeed, its nearby animal house has a capacity for producing hundreds of antibodies per annum by raising them in the systems of *Capra hircus* goats, giving researchers a way to ingratiate themselves with the community and make use of the existing agricultural structure for the good of medical progress. In essence, this method means that there is a mutually beneficial relationship between the rural goat farmers and the scientists incubating antibodies in order to further medical science.

With the production of antibodies against fluorescent proteins such as GFP, mCherry, tdTomato, and more, SICGEN Antibodies public has enjoyed publication across a variety of journals in Life Sciences papers across nature, cell, and broader scientific study. Moreover, it currently produces its polyclonal antibodies for the North American, European, and Far East market, marking it out as one of the most globally renowned and fast growing in the industry. This has certainly made it one to watch on the global antibody distribution stage.



With a small team and big ambitions, it produces products to the highest of standards and only lets those that have undergone its rigorous quality testing leave the lab, working hard since the start of the pandemic to help by focusing its efforts on the production of antibodies against the protein strains of SARS-Cov-2. With the support of the Portuguese government in the form of grants, its production has continued apace, allowing it to keep contributing its top-of-the-line solutions to the global medical ecosystem.



Company: SICGEN  
Contact: Jose Ramalho  
Website: <https://sicgen.pt/>

GHP Technology Awards 2022